HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Personal Folders Download to citation manager Permission Requests Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Rupinder, S. Articles by Muralidhar, K. Search for Related Content PubMed Articles by Rupinder, S. Articles by Muralidhar, K. Related Collections Cardiac - pharmacology Congenital - cyanotic

Aprotinin for Open Cardiac Surgery in Cyanotic Heart Disease

Department of Cardiac Anaesthesia 1 Department of Cardiac Surgery Manipal Heart Foundation Bangalore, Karnataka, India
For reprint information contact: Muralidhar Kanchi, MD Tel: 91 80 528 7748 Ext. 297 Fax: 91 80 526 8912 email: mhfbg{at}giasbg01.vsnl.net.in Department of Cardiac Anaesthesia, Manipal Heart Foundation, 98 Rustom Bagh, Airport Road, Bangalore, Karnataka 560017, India.

In a prospective randomized study, aprotinin was assessed in cyanotic children with tetralogy of Fallot undergoing total correction utilizing cardiopulmonary bypass. In group A (n = 25), 20,000 kallikrein inhibiting units of aprotinin per kilogram of body weight was administered before cardiopulmonary bypass and the same amount was added to the pump prime. In group B (n = 25), only a single dose of aprotinin was given before cardiopulmonary bypass. Blood loss and blood product requirements were compared with those in a control group of 25 patients who did not receive aprotinin. Blood loss and blood products used in groups A and B did not differ but the control group had significantly more bleeding and transfusion requirements. A single dose of aprotinin before cardiopulmonary bypass is recommended in cyanotic patients undergoing intracardiac repair.